Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by indaknownewfieon Feb 27, 2021 5:56pm
518 Views
Post# 32680002

Nitric Oxide Nasal Spray

Nitric Oxide Nasal Spray

Claritas believes that R-107 has potential to become an effective front-line therapy for patients who contract Covid-19 infection. R-107 is anticipated to be effective against all strains because its mechanism of action is not dependent upon the specifics of the viral structure. The Company believes that R-107 may also have potential as a prophylactic to prevent COVID-19 infection, and the Company intends to also develop R-107 as a nasal spray for this purpose.

Israel is also considering defining the spray as a medical device, NOT A DRUG, she added, (Gilly Regev, CEO Sanotize) which means it could get approval in that country much quicker. Directly from the Global news coverage about the NO spray from SaNOtize.

We know that Claritas has strong Isreali ties so its not far fetched to think our spray could be commercialized quickly

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse